RECEIVED CENTRAL FAX CENTER

OCT 2 4 2006

Johnson Johnson

3210 Merryfield Row San Diego, California 92121-1126 Phone: (858) 320-3406 Fax: (858) 784-3044

FACSIMILE COVER SHEET

Date: October 24, 2006

To: Commissioner for Patents

Attention: Examiner Dang, Art Unit 1647

Of: United States Patent and Trademark Office

Fax No.: 571-273-8300

From: Linda S. Evans

Total Pages (including this page): 3

Re: U.S. Patent Application No. 10/786,478, filed February

25, 2004

Applicant: Chen et al.

Attorney Docket No: PRD2045NP-US

Certificate of transmission:

The undersigned certifies that the accompanying Supplemental Response To Restriction Requirement is being transmitted to the above-referenced fax number on the above-identified date.

Linda S. Evans (Reg. No. 33,873)

CONFIDENTIALITY NOTICE: This facsimile transmission, including this cover sheet and any documents that may accompany it, contains information from Johnson & Johnson intended only for the use of the individual or entity to which it is addressed, which may contain information that is privileged, confidential, and/or otherwise exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, any disclosure, dissemination, distribution, copying or other use of this communication or its substance is prohibited. If you have received this communication in error, please call us "collect" to arrange for the destruction of the communication or its return to us at our expense. Thank

PAGE 1/3 * RCVD AT 10/24/2006 1:18:09 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/35 * DNIS:2738300 * CSID:858 784 3044 * DURATION (mm-ss):00-48

RECEIVED CENTRAL FAX CENTER

OCT 2 4 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chen et al. Atty Docket No.: PRD2045NP-US

Serial No.: 10/786,478 Art Unit: 1647

Filed: February 25, 2004 Examiner: Ian D. Dang

For: Relaxin3-GPCR135 Complexes Confirmation No.: 1497

And Their Production And Use

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This is a reply to the official communication mailed September 28, 2006. In the event any fees are required for the filing of this paper, including in connection with any necessary extension of time (for which Applicant hereby petitions), please charge such fees to Deposit Account No. 10-0750.

In the prior response dated August 14, 2006, Applicant overlooked addressing the election-of-species requirement included in the reasons provided in support of the restriction requirement set forth in the Office Action dated July 12, 2006. In particular, the election-of-species requirement calls for Applicant to elect a specific GPCR135 amino acid sequence for examination in connection with the elected invention.

Applicant hereby elects the species of the invention of elected Group I, claims 1-10, wherein the GPCR135 has the amino acid sequence of SEQ ID NO: 12. Claims 1-10 read on the elected species.

This election is with traverse for the following reasons. The requirement is improper because a reasonable number of additional species (e.g., wherein the GPCR135 has the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 15) can be

PAGE 2/3 * RCVD AT 10/24/2006 1:18:09 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/35 * DNIS:2738300 * CSID:858 784 3044 * DURATION (mm-ss):00-48

examined without imposing a serious burden. See 35 U.S.C. § 121 and M.P.E.P. § 803. See also, M.P.E.P. § 803.02 (if the members of a Markush group are sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden, all members must be examined on the merits) and § 803.04 (normally ten sequences constitute a reasonable number of nucleotide sequences for examination purposes). Furthermore, it is improper for the USPTO to refuse to examine that which Applicant regards as their invention, unless the subject matter in a claim lacks unity of invention. See M.P.E.P. § 803.02, citing <u>in re Hamisch</u>, 631 F.2d 716, 206 U.S.P.Q. 300 (CCPA 1980).

In view of the foregoing, Applicant respectfully requests prompt examination on the merits of not only the elected species within the scope of claims 1-10 of Group I, but also an extended scope of the elected claims embracing a reasonable number of additional species.

Respectfully submitted,

Date: October 24, 2006

Linda S. Evans Reg. No. 33,873

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933-7003 (858) 320-3406